DFTX Company Profile and Key Details

Definium Therapeutics, Inc. (NASDAQ:DFTX) closed at $38.92 USD, gaining $1.20 (3.17%) from the previous close of $37.73. The stock is currently mid-range between its 52-week high and low $12.88 and $49.20. With a market capitalization of about $5.17 billion, Definium Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.24). Key stats such as the average daily volume over the past year has been around 4.53 million shares, volume is running light vs its 52-week average. Headquartered in New York, NY, Definium Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Barrow, the company employs approximately 106 people and listed since November 15, 2016. Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders.

Definium Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.89. This means the shares are trading above this model’s fair value.

Definium Therapeutics, Inc. has 134.37 million shares outstanding. The public float is 124.50 million shares, elevated short interest at 8.15% of float. This equals 10.74 million shares. The short ratio is 5.24 days. Institutional investors hold 74.96% of the float. Insiders own 1.33%. Barrow Robert holds 1.49 million shares, Karlin Daniel has 503.28 thousand shares and Sullivan Mark has 320.57 thousand shares. Over the past six months, insider transactions show net selling. They sold 120.30 thousand shares across 9 transactions.

DFTX has shown sold momentum, gaining 20.89% over the past week and 22.93% over the past quarter, though year-to-date performance is up 25.32%. Short-term trend indicators are bearishly aligned (SMA20 0.97%, SMA50 11.63%, SMA200 53.73%). The stock’s 14-day RSI is 55.31 (neutral), while the ATR of 1.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.54% below its high and over 267.87% above its low. Average 10-day trading volume of 1.40 million shares is below the 3-month average of 2.82 million, indicating normal recent market interest.

Definium Therapeutics, Inc. generated EPS of -$1.97 over the past year. Five-year average earnings growth is 12.11%. Wall Street analysts project EPS growth of -0.05% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $74.00 to $25.00. The high target offers 96.13% upside. The low target suggests -33.74% downside. The mean target is $50.60. This offers 34.11% upside. Definium Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 06, 2026, missed forecasts by 166.19%. The prior quarter beat by 44.27%. Over the last six quarters, Apple has recorded several small beats. These include -2.78% in May 08, 2025.

Our AI price prediction model suggests that Definium Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.73%, with price expected at $32.55 by September 24, 2026, within a range of $30.81 to $34.42 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 09, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected gain of 153.78%, with price at $95.75 by September 10, 2027, within a range of $95.02 to $96.54.

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares are up 25.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Definium Therapeutics, Inc. trading at a premium to the broader market with a P/E of -10.92. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $50.60, suggesting 34.11% upside. Our AI forecast model points to short-term weakness (-13.73% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (153.78% over one year), with expected trading ranges indicating moderate volatility.

Definium Therapeutics, Inc. trades at a P/E ratio of -10.92, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.53 trading at moderately above to book value. The P/FCF stands at -29.88, also below market averages.